20.500.12556/RUL-135949 Bleomycin concentration in patientsʹ plasma and tumors after electrochemotherapy a study from InspECT Group The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effective tumor response are not known. In this study, the pharmacokinetic profile of bleomycin in the distribution phase in 12 patients younger than 65 years was determined. In 17 patients, the intratumoral bleomycin concentration was determined before the application of electric pulses. In younger patients, the pharmacokinetics of intravenously injected bleomycin demonstrated a faster plasma clearance rate than that in patients older than 65 years. This outcome might indicate that the lowering of the standard bleomycin dose of 15,000 IU/m$^2$ with intravenous bleomycin injection for electrochemotherapy is not recommended in younger patients. Based on the plasma concentration data gathered, a time interval for electrochemotherapy of 5–15 min after bleomycin injection was determined. The median bleomycin concentration in tumors 8 min after bleomycin injection, at the time of electroporation, was 170 ng/g. Based on collected data, the reduction of the bleomycin dose is not recommended in younger patients; however, a shortened time interval for application of electric pulses in electrochemotherapy to 5–15 min after intravenous bleomycin injection should be considered. electrochemotherapy electroporation bleomycin pharmacokinetics blood samples tumor samples drug delivery elektrokemoterapija elektroporacija bleomycin true false true Angleški jezik Slovenski jezik Članek v reviji 2022-04-04 10:00:57 2022-04-04 10:00:57 2022-09-15 04:12:54 0000-00-00 00:00:00 2021 0 0 12 str. iss. 9, art. 1324 Vol. 13 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 602.6/.7 1999-4923 10.3390/pharmaceutics13091324 74740739 RAZ_Groselj_Ales_2021.pdf RAZ_Groselj_Ales_2021.pdf 1 DDAC435A4B25BBF8ACF9B91BE59F2F51 f449995d67e0f1d17f69b0589a106e9726fff390c5b0d37531248689c3122f66 ae95abf2-b3ed-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155275 https://www.mdpi.com/1999-4923/13/9/1324 1 5578394c-b3ed-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155274 Medicinska fakulteta Fakulteta za farmacijo Zdravstvena fakulteta 0 0 0